Inflammation of actinic keratosis from chemotherapy in a relapsed multiple myeloma patient DOI
Abdul Moiz Khan,

Tarec Micho Ulbeh,

Jeffrey A. Zonder

et al.

BMJ Case Reports, Journal Year: 2023, Volume and Issue: 16(11), P. e256024 - e256024

Published: Nov. 1, 2023

A man in his 60 s with a history of actinic keratosis (AK) and relapsed IgG kappa multiple myeloma (MM) recently received VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) chemotherapy presented numerous haemorrhagic, scaly lesions on scalp face. He also had sepsis from methicillin-sensitive Staphylococcus aureus (MSSA) bacteraemia. Since the were only present areas pre-existing AK, diagnosis inflammation AK secondary to was made. Sepsis treated appropriate antibiotics, managed topical steroids, leading complete recovery.

Language: Английский

Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways DOI Creative Commons
Mario E. Lacouture, Elena Goleva, Neil J. Shah

et al.

Clinical Cancer Research, Journal Year: 2024, Volume and Issue: 30(13), P. 2822 - 2834

Published: April 23, 2024

Abstract Purpose: Immune-related cutaneous adverse events (ircAE) occur in ≥50% of patients treated with checkpoint inhibitors, but the underlying mechanisms for ircAEs are poorly understood. Experimental Design: Phenotyping/biomarker analyses were conducted 200 on inhibitors [139 and 61 without (control group)] to characterize their clinical presentation immunologic endotypes. Cytokines evaluated skin biopsies, tape strip extracts, plasma using real-time PCR Meso Scale Discovery multiplex cytokine assays. Results: Eight ircAE phenotypes identified: pruritus (26%), maculopapular rash (MPR; 21%), eczema (19%), lichenoid (11%), urticaria (8%), psoriasiform (6%), vitiligo (5%), bullous dermatitis (4%). All showed lymphocyte eosinophil infiltrates. Skin biopsy revealed highest increase IFNγ mRNA (P < 0.0001) 0.01) as compared ircAEs, whereas IL13 levels detected 0.0001, control). IL17A was selectively increased 0.001), 0.0001), 0.05), MPR 0.001) control. Distinct profiles confirmed plasma. Analysis determined skin/plasma IL4 pruritus, eczema, IL5 IL31 urticaria, mixed-cytokine pathways MPR. Broad inhibition via corticosteroids or type 2 cytokine–targeted resulted benefit these ircAEs. In contrast, significant upregulation 1/type 17 found psoriasiform, lichenoid, dermatitis, 1 activation vitiligo. Conclusions: endotypes suggest actionable targets precision medicine-based interventions.

Language: Английский

Citations

6
Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience DOI Creative Commons
Martina Merli,

Martina Accorinti,

Maurizio Romagnuolo

et al.

Frontiers in Medicine, Journal Year: 2023, Volume and Issue: 10

Published: July 20, 2023

Cutaneous immune-related adverse events are frequently associated with immune checkpoint inhibitors (ICIs) administration in cancer patients. In fact, these monoclonal antibodies bind the cytotoxic T-lymphocyte antigen-4 and programmed cell death-1/ligand 1 leading to a non-specific activation of system against both tumoral cells self-antigens. The skin is most affected organ appearing involved especially by inflammatory manifestations such as maculopapular, lichenoid, psoriatic, eczematous eruptions. Although less common, ICI-induced autoimmune blistering diseases have also been reported, an estimated overall incidence than 5%. Bullous pemphigoid-like eruption predominant phenotype, while lichen planus pemphigoides, pemphigus vulgaris, mucous membrane pemphigoid described anecdotally. Overall, they wide range clinical presentations often overlap each other delayed diagnosis. Achieving adequate control toxicity cases requires immunosuppressive systemic therapies and/or interruption ICI treatment, presenting therapeutic challenge context management. this study, we present case series from Italy based on multicenter, retrospective, observational which included 45 patients treated ICIs who developed bullous pemphigoid. addition, performed comprehensive review identify reported literature diseases. Several theories seeking their underlying pathogenesis work aims better understand what known so far issue.

Language: Английский

Citations

12
Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma DOI Open Access
Taku Fujimura, Yusuke Muto, Yoshihide Asano

et al.

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(24), P. 15720 - 15720

Published: Dec. 11, 2022

Therapeutic options for treating advanced melanoma have progressed rapidly in recent decades. Until 6 years ago, the regimen consisted mainly of cytotoxic agents such as dacarbazine and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies been recognized anchor drugs melanoma, with or without additional combination ipilimumab, but efficacies these immunotherapies are not fully satisfactory. In this review, we describe development currently available anti-PD1 Abs-based focusing on their efficacy immune-related adverse events (AEs), well clinical trials still ongoing future treatment melanoma.

Language: Английский

Citations

17
Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence DOI Open Access

Abdulaziz M. Eshaq,

Thomas W. Flanagan,

Anass Abbad

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 26(1), P. 88 - 88

Published: Dec. 26, 2024

Immunotherapy, particularly that based on blocking checkpoint proteins in many tumors, including melanoma, Merkel cell carcinoma, non-small lung cancer (NSCLC), triple-negative breast (TNB cancer), renal cancer, and gastrointestinal endometrial neoplasms, is a therapeutic alternative to chemotherapy. Immune inhibitor (ICI)-based therapies have the potential target different pathways leading destruction of cells. Although ICIs are an effective treatment strategy for patients with highly immune-infiltrated cancers, development adverse effects cutaneous during after common. ICI-associated include mostly inflammatory bullous dermatoses, as well severe side reactions such rash or dermatitis encompassing erythema multiforme; lichenoid, eczematous, psoriasiform, morbilliform lesions; palmoplantar erythrodysesthesia. The immunotherapy-related consequence ICIs’ unique molecular action mainly mediated by activation cytotoxic CD4+/CD8+ T disorders most prevalent induced response anti-programmed death 1 (PD-1), anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), ligand (PD-L1) agents. Herein, we will elucidate mechanisms regulating occurrence following ICIs.

Language: Английский

Citations

0
Immune checkpoint inhibitor-induced cutaneous toxicities: a review of histopathologic and clinical features DOI

J Martel,

Hannah L. Hanania, Anisha B. Patel

et al.

Human Pathology, Journal Year: 2023, Volume and Issue: 140, P. 144 - 172

Published: May 2, 2023

Language: Английский

Citations

1
Immunological Mechanisms in Cutaneous Adverse Drug Reactions DOI Creative Commons
Ai‐Young Lee

Biomolecules & Therapeutics, Journal Year: 2023, Volume and Issue: 32(1), P. 1 - 12

Published: Dec. 27, 2023

Adverse drug reactions (ADRs) are an inherent aspect of use. While approximately 80% ADRs predictable, immune system-mediated ADRs, often unpredictable, a noteworthy subset. Skin-related in particular, frequently unpredictable. However, the wide spectrum skin manifestations poses formidable diagnostic challenge. Comprehending pathomechanisms underlying is essential for accurate diagnosis and effective management. The skin, being active organ, plays pivotal role although precise cutaneous immunological mechanisms remain elusive. Fortunately, clinical skin-related irrespective their severity, rooted processes. A comprehensive grasp ADR morphology can aid diagnosis. With continuous development new pharmaceuticals, it that certain drugs including checkpoint inhibitors have gained notoriety association with ADRs. This paper offers overview involved focus on features implicated drugs.

Language: Английский

Citations

1
Cutaneous adverse events due to checkpoint inhibitors – a retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022 DOI Creative Commons

Clara Furrer-Matcau,

Chloé Sieber, Dirk Lehnick

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Dec. 5, 2024

Checkpoint inhibitors are increasingly important in anti-cancer treatment. Therefore, knowledge of immune-related cutaneous adverse events (ir-cAE) is crucial for therapy management and continuation.

Language: Английский

Citations

0
Advancing dermatology: artificial intelligence-based solutions to reducing the risk of misdiagnosis DOI
Ilya Klabukov, Denis Baranovskii

Clinical and Experimental Dermatology, Journal Year: 2023, Volume and Issue: 49(7), P. 731 - 732

Published: Sept. 14, 2023

Artificial intelligence has potential applications in dermatology reducing rates of misdiagnosis. Despite evidence-based recommendations, misdiagnosis still occurs due to the complexity problem. Multispectral imaging, such as near- and far-infrared aid identification skin malignancies.

Language: Английский

Citations

0
Inflammation of actinic keratosis from chemotherapy in a relapsed multiple myeloma patient DOI
Abdul Moiz Khan,

Tarec Micho Ulbeh,

Jeffrey A. Zonder

et al.

BMJ Case Reports, Journal Year: 2023, Volume and Issue: 16(11), P. e256024 - e256024

Published: Nov. 1, 2023

A man in his 60 s with a history of actinic keratosis (AK) and relapsed IgG kappa multiple myeloma (MM) recently received VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) chemotherapy presented numerous haemorrhagic, scaly lesions on scalp face. He also had sepsis from methicillin-sensitive Staphylococcus aureus (MSSA) bacteraemia. Since the were only present areas pre-existing AK, diagnosis inflammation AK secondary to was made. Sepsis treated appropriate antibiotics, managed topical steroids, leading complete recovery.

Language: Английский

Citations

0